Boston Scientific delivered an exceptional third quarter of 2025 with strong performance across businesses and regions, exceeding guidance for both net sales and EPS, driven by category leadership and innovation.
Net sales of $5.065 billion grew 20.3% on a reported basis, exceeding guidance of 17-19%.
positiveGAAP EPS of $0.51 exceeded guidance of $0.44-$0.46.
positiveAdjusted EPS of $0.75 exceeded guidance of $0.70-$0.72.
positiveCardiovascular segment net sales grew 22.4% reported, 21.5% operational, and 19.4% organic.
positiveU.S. net sales grew 27.0% reported and operational.
positiveDiscontinuation of worldwide sales for ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarter.
attentionOrganic net sales growth in MedSurg was 7.6%, significantly lower than Cardiovascular's 19.4%.
attentionEMEA reported net sales grew only 2.6% and declined 2.0% operationally.
negativeOrganic net sales growth in Urology was 5.4%, impacted by a 22.1% divestiture impact.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Delivered another exceptional quarter of strong performance across businesses and regions.
Well-positioned for differentiated growth fueled by category leadership strategy.
Relentless focus on innovation and commitment to scaling capabilities.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.